Literature DB >> 15879837

Outcome of gonadotropin therapy for male hypogonadotropic hypogonadism at university affiliated male infertility centers: a 30-year retrospective study.

Yasushi Miyagawa1, Akira Tsujimura, Kiyomi Matsumiya, Tetsuya Takao, Akira Tohda, Minoru Koga, Masami Takeyama, Hideki Fujioka, Shingo Takada, Takuo Koide, Akihiko Okuyama.   

Abstract

PURPOSE: Hypogonadotropic hypogonadism (HH) is an uncommon cause of male infertility. Even specialized centers see small numbers of patients and have little experience in restoring fertility in these patients. To explore the phenotypic heterogeneity and treatment outcome of HH, we summarized our 30-year experience.
MATERIALS AND METHODS: Medical charts of 36 male patients (age range 11 to 42 years) with HH (81% primary, 19% secondary) treated at university affiliated male infertility centers were reviewed. Pubic hair stage, genital stage, testicular volume (TV), sexual function and sperm production were determined before and after human chorionic gonadotropin/human menopausal gonadotropin (hCG/hMG) treatment. Differences were analyzed statistically.
RESULTS: The population was stratified according to initial TV into a small testis subset (TV less than 4 ml in 23) and a large testis subset (TV 4 ml or greater in 13). Comparison of these 2 subsets revealed significant differences in the incidence of cryptorchidism (39% vs 8%) and Kallmann's syndrome (22% vs 0%), pubic hair stage (1.3 +/- 0.5 vs 3.5 +/- 1.4), genital stage (1.2 +/- 0.4 vs 3.9 +/- 0.9) and TV (1.6 +/- 0.9 vs 7.5 +/- 3.5 ml). Long-term administration of hCG/hMG for 12 to 240 months (average 56 +/- 11) resulted in sperm production in only 36% of the small testis subjects but in 71% of the large testis subjects.
CONCLUSIONS: Initial TV values provide insight into phenotypic variables such as time of onset and severity in patients with primary or secondary HH, and may predict sperm output in response to hCG/hMG therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879837     DOI: 10.1097/01.ju.0000158133.09197.f4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

1.  [Kallmann syndrome].

Authors:  A Mokosch; C Bernecker; H S Willenberg; N J Neumann
Journal:  Hautarzt       Date:  2011-10       Impact factor: 0.751

2.  Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience.

Authors:  Luo Yang; Si Xiao Zhang; Qiang Dong; Zi Bing Xiong; Xiang Li
Journal:  Int Urol Nephrol       Date:  2011-10-12       Impact factor: 2.370

Review 3.  Recent topics related to testosterone deficiency syndrome in Japan.

Authors:  Akira Tsujimura; Norio Nonomura
Journal:  Asian J Androl       Date:  2011-04-04       Impact factor: 3.285

Review 4.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.

Authors:  Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2015-07-21       Impact factor: 43.330

Review 5.  Testosterone therapy in children and adolescents: to whom, how, when?

Authors:  Maria Camila Suarez A; Joseph M Israeli; Eliyahu Kresch; Leon Telis; Daniel E Nassau
Journal:  Int J Impot Res       Date:  2022-01-07       Impact factor: 2.896

6.  Treatment of congenital hypogonadotropic hypogonadism in male patients.

Authors:  Hae Sang Lee; Young Suk Shim; Jin Soon Hwang
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-09-30

Review 7.  Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS).

Authors:  Ankit Desai; Musaab Yassin; Axel Cayetano; Tharu Tharakan; Channa N Jayasena; Suks Minhas
Journal:  Ther Adv Urol       Date:  2022-06-26

8.  Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism.

Authors:  Rafif Farhat; Fatma Al-zidjali; Ali S Alzahrani
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

9.  Recombinant follitropin alfa/lutropin alfa in fertility treatment.

Authors:  Ahmed Gibreel; Siladitya Bhattacharya
Journal:  Biologics       Date:  2010-02-04

10.  Reproductive outcomes of microdissection testicular sperm extraction in hypogonadotropic hypogonadal azoospermic men after gonadotropin therapy.

Authors:  Yu-Kuang Chen; I-Shen Huang; Wei-Jen Chen; Chen-Yu Huang; Chi-Hong Ho; Eric Yi-Hsiu Huang; William J Huang
Journal:  J Assist Reprod Genet       Date:  2021-05-12       Impact factor: 3.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.